To investigate the impact of renal impairment (RI) on the efficacy of first-line chemotherapy in patients with locally advanced or metastatic upper tract urothelial carcinoma (la/mUTUC).

Methods

This multicenter retrospective study evaluated 300 patients with la/mUTUC who received GEM/CDDP or GEM/CBDCA as first-line chemotherapy. RI was defined as eGFR < 45 mL/min/1.73 m² and used to categorize patients into RI and without-RI groups. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were analyzed. Multivariable Cox proportional hazard analysis was conducted to assess risk factors for PFS and OS. In the RI group, oncologic outcomes were compared between GEM/CDDP and GEM/CBDCA.

Results

Overall, 130 patients (43%) had RI, and 170 (57%) did not. During a median follow-up of 32 months, 188 patients (63%) died: 74 patients (56%) in the RI group and 114 (67%) in the without-RI group. Among 288 evaluable patients, the ORR was 34% in the RI group and 45% in the without-RI group (p = 0.072). The median PFS of the RI and without-RI groups was 5.6 and 4.8 months, respectively (p = 0.322), and the median OS was 16.9 and 14.5 months, respectively (p = 0.074). Among the RI group, no significant differences were observed between GEM/CDDP and GEM/CBDCA in PFS (6.4 vs. 4.2 months, p = 0.113) or OS (21.4 vs. 15.2 months, p = 0.142).

Conclusions

In la/mUTUC, oncologic outcomes were comparable between patients with and without RI. In the RI group, responses to GEM/CDDP and GEM/CBDCA did not differ.

Conflicts of Interest

H.T. and Y.F. are the Editorial Board members of the International Journal of Urology and the co-authors of this article. To minimize bias, they were excluded from all editorial decision-making.

Supporting Information

References

1M. De Santis, J. Bellmunt, G. Mead, et al., “Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986,” Journal of Clinical Oncology 30, no. 2 (2012): 191–199.
10.1200/JCO.2011.37.3571
CAS PubMed Web of Science® Google Scholar
2M. D. Galsky, N. M. Hahn, J. Rosenberg, et al., “Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy,” Journal of Clinical Oncology 29, no. 17 (2011): 2432–2438.
10.1200/JCO.2011.34.8433
PubMed Web of Science® Google Scholar
3Y. Okuyama, S. Hatakeyama, R. Tabata, et al., “Impact of Nephroureterectomy on Postoperative Renal Function in Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study,” International Journal of Urology 30, no. 8 (2023): 649–657.
10.1111/iju.15192
CAS PubMed Web of Science® Google Scholar
4L. Dogliotti, G. Cartenì, S. Siena, et al., “Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial,” European Urology 52, no. 1 (2007): 134–141.
10.1016/j.eururo.2006.12.029
CAS PubMed Web of Science® Google Scholar
5Y. Fujii, Y. Sato, H. Suzuki, et al., “Molecular Classification and Diagnostics of Upper Urinary Tract Urothelial Carcinoma,” Cancer Cell 39, no. 6 (2021): 793–809.
10.1016/j.ccell.2021.05.008
CAS PubMed Web of Science® Google Scholar
6X. Su, X. Lu, S. K. Bazai, et al., “Comprehensive Integrative Profiling of Upper Tract Urothelial Carcinomas,” Genome Biology 22, no. 1 (2021): 7.
10.1186/s13059-020-02230-w
CAS PubMed Web of Science® Google Scholar
7H. D. Kim, H. S. Im, J. H. Kim, et al., “Use of Gemcitabine Plus Carboplatin Is Associated With Poor Outcomes in Urothelial Carcinoma Patients With Chronic Kidney Disease Stage 4-5,” Cancer Research and Treatment 53, no. 4 (2021): 1166–1173.
10.4143/crt.2021.091
PubMed Web of Science® Google Scholar
8E. Xylinas, M. Rink, V. Margulis, et al., “Impact of Renal Function on Eligibility for Chemotherapy and Survival in Patients Who Have Undergone Radical Nephro-Ureterectomy,” BJU International 112, no. 4 (2013): 453–461.
10.1111/j.1464-410X.2012.11649.x
CAS PubMed Web of Science® Google Scholar
9J. Bellmunt, T. K. Choueiri, R. Fougeray, et al., “Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens,” Journal of Clinical Oncology 28, no. 11 (2010): 1850–1855.
10.1200/JCO.2009.25.4599
PubMed Web of Science® Google Scholar
10M. Fujiwara, T. Yuasa, T. Urasaki, et al., “Effectiveness and Safety Profile of Pembrolizumab for Metastatic Urothelial Cancer: A Retrospective Single-Center Analysis in Japan,” Cancer Reports 4 (2021): 6–11.
10.1002/cnr2.1398
Web of Science® Google Scholar
11J. I. de Ulíbarri, A. González-Madroño, N. G. P. de Villar, et al., “CONUT: A Tool for Controlling Nutritional Status. First Validation in a Hospital Population,” Nutrición Hospitalaria 20, no. 1 (2005): 38–45.
Google Scholar
12E. A. Eisenhauer, P. Therasse, J. Bogaerts, et al., “New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1),” European Journal of Cancer 45, no. 2 (2009): 228–247.
10.1016/j.ejca.2008.10.026
CAS PubMed Web of Science® Google Scholar
13Y. Kanda, “Investigation of the Freely Available Easy-To-Use Software “EZR” for Medical Statistics,” Bone Marrow Transplantation 48, no. 3 (2013): 452–458.
10.1038/bmt.2012.244
CAS PubMed Web of Science® Google Scholar
14J. Bellmunt and D. P. Petrylak, “New Therapeutic Challenges in Advanced Bladder Cancer,” Seminars in Oncology 39, no. 5 (2012): 598–607.
10.1053/j.seminoncol.2012.08.007
CAS PubMed Web of Science® Google Scholar
15T. Powles, B. P. Valderrama, S. Gupta, et al., “Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer,” New England Journal of Medicine 390, no. 10 (2024): 875–888.
10.1056/NEJMoa2312117
CAS PubMed Web of Science® Google Scholar
16E. Grande, A. J. Birtle, and A. M. Kamat, “Re: Thomas Powles, Begoña Pérez-Valderrama, Shilpa Gupta, Et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024;390:875–88,” European Urology 86, no. 6 (2024): 152–e153.
10.1016/j.eururo.2024.06.022
Web of Science® Google Scholar
17T. Murakami, E. Kikuchi, H. Ide, et al., “Oncological Outcomes of Dose Reductions in Cisplatin due to Renal Dysfunction for Patients With Metastatic Urothelial Carcinoma,” BJUI Compass 2 (2021): 322–330.
10.1002/bco2.81
PubMed Web of Science® Google Scholar
18S. Yoshida, Y. Maezawa, K. Ishihara, et al., “Outcomes and Prognostic Factors in Patients With Synchronous and Metachronous Oligometastatic Urothelial Carcinoma With Visceral Metastases,” International Journal of Urology 31 (2024): 1234–1240.
10.1111/iju.15542
CAS PubMed Web of Science® Google Scholar
19T. W. Flaig, P. E. Spiess, M. Abern, et al., “NCCN Guidelines Insights: Bladder Cancer, Version 2.2022,” Journal of the National Comprehensive Cancer Network 20, no. 8 (2022): 866–878.
10.6004/jnccn.2022.0041
PubMed Google Scholar
20M. Rouprêt, M. Babjuk, M. Burger, et al., “European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update,” European Urology 79, no. 1 (2021): 62–79.
10.1016/j.eururo.2020.05.042
CAS PubMed Web of Science® Google Scholar
21K. Sugimoto, S. Taguchi, K. Kishitani, et al., “Comparison of Full-Dose Gemcitabine/Cisplatin, Dose-Reduced Gemcitabine/Cisplatin, and Gemcitabine/Carboplatin in Real-World Patients With Advanced Urothelial Carcinoma,” BMC Urology 22, no. 1 (2022): 177.
10.1186/s12894-022-01139-9
CAS PubMed Web of Science® Google Scholar
22J. Bellmunt, R. de Wit, D. J. Vaughn, et al., “Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma,” New England Journal of Medicine 376, no. 11 (2017): 1015–1026.
10.1056/NEJMoa1613683
CAS PubMed Web of Science® Google Scholar
23Y. Fradet, J. Bellmunt, D. J. Vaughn, et al., “Randomized Phase III KEYNOTE-045 Trial of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine in Recurrent Advanced Urothelial Cancer: Results of > 2 Years of Follow-Up,” Annals of Oncology 30, no. 6 (2019): 970–976.
10.1093/annonc/mdz127
CAS PubMed Web of Science® Google Scholar
24J. Bellmunt, S. Albiol, C. Suárez, and J. Albanell, “Optimizing Therapeutic Strategies in Advanced Bladder Cancer: Update on Chemotherapy and the Role of Targeted Agents,” Critical Reviews in Oncology/Hematology 69, no. 3 (2009): 211–222.
10.1016/j.critrevonc.2008.06.002
CAS PubMed Web of Science® Google Scholar
25A. Y. Abuhelwa, J. Bellmunt, G. Kichenadasse, et al., “Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy,” Clinical Genitourinary Cancer 20, no. 2 (2022): 132–138.
10.1016/j.clgc.2021.11.010
PubMed Web of Science® Google Scholar

Early View

Online Version of Record before inclusion in an issue

Filename	Description
iju70136-sup-0001-FigureS1.pdfPDF document, 50.7 KB	Figure S1. (a) Kaplan–Meier curves of overall survival (OS) stratified by treatment era: before 2016 and since 2017. (b) Kaplan–Meier curves for overall survival (OS) stratified by treatment regimen and era: GEM/CDDP before 2016, GEM/CBDCA before 2016, GEM/CDDP since 2017, and GEM/CBDCA since 2017.
iju70136-sup-0002-Tables.docxWord 2007 document , 35.2 KB	Data S1.

Real-World Outcomes of First-Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study)

ABSTRACT

Objectives

Methods

Results

Conclusions

Conflicts of Interest

Supporting Information

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Real-World Outcomes of First-Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study)

ABSTRACT

Objectives

Methods

Results

Conclusions

Conflicts of Interest

Supporting Information

References

References

Related

Information